Lymphoma

I share how walking has helped me through lymphoma, knee surgeries and treatments, and why staying active keeps me physically, mentally and spiritually strong.

Stage 2 lymphoma is treatable. Diagnosis and treatment depend on subtype, but most patients achieve excellent outcomes with modern therapies.

Even after all these years with small lymphocytic lymphoma, I’ve accepted that the scares will never completely go away — but neither will my resilience.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

The FDA granted breakthrough therapy designation to sonrotoclax for adults with relapsed or refractory mantle cell lymphoma, based on phase 1/2 data.

Lymphoma is a treatable cancer of the immune system; early diagnosis and personalized treatment with chemo and radiation often lead to a cure.

For patients with relapsed/refractory mantle cell lymphoma Lunsumio plus Polivy was associated with durable responses.

The FDA approved Monjuvi with Revlimid and Rituxan for follicular lymphoma, the same combination that brought survivor Troy Anderson a lasting response.

Autumn lifts my spirit, reminding me to embrace beauty, family, faith, and gratitude even while living with cancer.

ctDNA-MRD testing better predicted outcomes versus PET/CT scans for large B-cell lymphoma, leading to NCCN guideline updates for remission assessment.

Writing and reading help me stay grounded and find meaning while living with chronic cancer, balancing health, family and speaking out against hatred.

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma after two prior therapies.

When treatment ended, people expected relief, but what I felt was loss, fear, and the weight of a life forever changed.

Writing poems following my lymphoma diagnosis gave me hope and purpose as I endured chemo, helping me heal and share my experience with others.

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, according to Dr. Christina Poh.

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.

A patient on the Monjuvi trial saw lymph nodes shrink 85%, with stable results a year later, supporting the FDA’s recent approval for follicular lymphoma.

Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of cancer never fully fade.

After nearly 11 years of living with Hodgkin lymphoma, my sister Kathleen passed away peacefully at 38, leaving me to navigate the sorrow of losing her.

Daniel Jernazian, a two-time cancer survivor, shares how sports, advocacy and meeting his idol shaped his journey through illness and recovery.

Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.

Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.

Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.

The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.